Skip to main content
MRK
NYSE Life Sciences

美国FDA批准默克的新联合HIV治疗

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$112.55
Mkt Cap
$278.268B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

美国食品和药物管理局(FDA)已经批准了默克的每日一次、口服、联合治疗HIV感染的方案。这一重要的监管胜利加强了默克的产品管道,并在竞争激烈的HIV市场中提供了一种新的治疗选择。该批准是公司的一个积极发展,尤其是其畅销的肿瘤学药物Keytruda面临未来的专利到期和价格压力。这一消息也有助于抵消默克和埃斯艾的实验性肾癌治疗未能达到其主要目标的早些时候的挫折。交易者将密切监视这一新HIV治疗的市场反应和销售预测。

在该公告发布时,MRK的交易价格为$112.55,交易所为NYSE,所属行业为Life Sciences,市值约为$2782.7亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为积极市场情绪,重要性评分为8/10。 来源:Reuters。


show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8